Getting a first look at the population that responds to Tus/Ven double will be highly informative, especially versus Tus alone. Furthermore the big question right now is how myleo-suppressive is the combination. The design of a registrational double trial will become clear AFTER they meet with the FDA. They need this initial data for that meeting.
I think a ven only arm in this patient population will be judged unethical. It won't happen.
News 
Market Data 
Discover 
